$ENTA Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ENANTA PHARMACEUTICALS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in ENANTA PHARMACEUTICALS INC. Get notifications about new insider transactions in ENANTA PHARMACEUTICALS INC for free.
Page: < prev 1 2 3 4 5 5 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 13 2019 | ENTA | ENANTA PHARMACEUTI ... | CARTER BRUCE L A | Director | Sell | S | 90.02 | 2,734 | 246,102 | 0 | 2.7 K to 0 (-100.00 %) |
Feb 13 2019 | ENTA | ENANTA PHARMACEUTI ... | CARTER BRUCE L A | Director | Buy | M | 23.40 | 2,734 | 63,976 | 2,734 | 0 to 2.7 K |
Feb 13 2019 | ENTA | ENANTA PHARMACEUTI ... | Ocain Tim | Senior Vice Preside ... | Payment of Exercise | F | 88.88 | 4,580 | 407,070 | 17,547 | 22.1 K to 17.5 K (-20.70 %) |
Feb 13 2019 | ENTA | ENANTA PHARMACEUTI ... | Ocain Tim | Senior Vice Preside ... | Payment of Exercise | F | 88.88 | 4,580 | 407,070 | 17,547 | 22.1 K to 17.5 K (-20.70 %) |
Feb 13 2019 | ENTA | ENANTA PHARMACEUTI ... | Ocain Tim | Senior Vice Preside ... | Grant | A | 0.00 | 10,000 | 0 | 22,127 | 12.1 K to 22.1 K (+82.46 %) |
Feb 13 2019 | ENTA | ENANTA PHARMACEUTI ... | Ocain Tim | Senior Vice Preside ... | Grant | A | 0.00 | 10,000 | 0 | 22,127 | 12.1 K to 22.1 K (+82.46 %) |
Feb 13 2019 | ENTA | ENANTA PHARMACEUTI ... | Ocain Tim | Senior Vice Preside ... | Grant | A | 0.00 | 4,000 | 0 | 12,127 | 8.1 K to 12.1 K (+49.22 %) |
Feb 13 2019 | ENTA | ENANTA PHARMACEUTI ... | Ocain Tim | Senior Vice Preside ... | Grant | A | 0.00 | 4,000 | 0 | 12,127 | 8.1 K to 12.1 K (+49.22 %) |
Feb 13 2019 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Payment of Exercise | F | 88.88 | 5,356 | 476,041 | 10,394 | 15.8 K to 10.4 K (-34.01 %) |
Feb 13 2019 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Payment of Exercise | F | 88.88 | 5,356 | 476,041 | 10,394 | 15.8 K to 10.4 K (-34.01 %) |
Feb 13 2019 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Grant | A | 0.00 | 11,250 | 0 | 15,750 | 4.5 K to 15.8 K (+250.00 %) |
Feb 13 2019 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Grant | A | 0.00 | 11,250 | 0 | 15,750 | 4.5 K to 15.8 K (+250.00 %) |
Feb 13 2019 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Grant | A | 0.00 | 4,500 | 0 | 4,500 | 0 to 4.5 K |
Feb 13 2019 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Grant | A | 0.00 | 4,500 | 0 | 4,500 | 0 to 4.5 K |
Feb 13 2019 | ENTA | ENANTA PHARMACEUTI ... | Gardiner Nathaniel S. | Sr. VP & General Co ... | Sell | S | 95.28 | 3,270 | 311,562 | 23,978 | 27.2 K to 24 K (-12.00 %) |
Feb 13 2019 | ENTA | ENANTA PHARMACEUTI ... | Gardiner Nathaniel S. | Sr. VP & General Co ... | Sell | S | 95.28 | 3,270 | 311,562 | 23,978 | 27.2 K to 24 K (-12.00 %) |
Feb 13 2019 | ENTA | ENANTA PHARMACEUTI ... | Gardiner Nathaniel S. | Sr. VP & General Co ... | Payment of Exercise | F | 88.88 | 4,579 | 406,982 | 27,248 | 31.8 K to 27.2 K (-14.39 %) |
Feb 13 2019 | ENTA | ENANTA PHARMACEUTI ... | Gardiner Nathaniel S. | Sr. VP & General Co ... | Payment of Exercise | F | 88.88 | 4,579 | 406,982 | 27,248 | 31.8 K to 27.2 K (-14.39 %) |
Feb 13 2019 | ENTA | ENANTA PHARMACEUTI ... | Gardiner Nathaniel S. | Sr. VP & General Co ... | Grant | A | 0.00 | 10,000 | 0 | 31,827 | 21.8 K to 31.8 K (+45.81 %) |
Feb 13 2019 | ENTA | ENANTA PHARMACEUTI ... | Gardiner Nathaniel S. | Sr. VP & General Co ... | Grant | A | 0.00 | 10,000 | 0 | 31,827 | 21.8 K to 31.8 K (+45.81 %) |
Feb 13 2019 | ENTA | ENANTA PHARMACEUTI ... | Gardiner Nathaniel S. | Sr. VP & General Co ... | Grant | A | 0.00 | 4,000 | 0 | 21,827 | 17.8 K to 21.8 K (+22.44 %) |
Feb 13 2019 | ENTA | ENANTA PHARMACEUTI ... | Gardiner Nathaniel S. | Sr. VP & General Co ... | Grant | A | 0.00 | 4,000 | 0 | 21,827 | 17.8 K to 21.8 K (+22.44 %) |
Feb 13 2019 | ENTA | ENANTA PHARMACEUTI ... | MELLETT PAUL J | Treasurer and CFO | Payment of Exercise | F | 88.88 | 4,890 | 434,623 | 90,228 | 95.1 K to 90.2 K (-5.14 %) |
Feb 13 2019 | ENTA | ENANTA PHARMACEUTI ... | MELLETT PAUL J | Treasurer and CFO | Payment of Exercise | F | 88.88 | 4,890 | 434,623 | 90,228 | 95.1 K to 90.2 K (-5.14 %) |
Feb 13 2019 | ENTA | ENANTA PHARMACEUTI ... | MELLETT PAUL J | Treasurer and CFO | Grant | A | 0.00 | 10,500 | 0 | 95,118 | 84.6 K to 95.1 K (+12.41 %) |
Feb 13 2019 | ENTA | ENANTA PHARMACEUTI ... | MELLETT PAUL J | Treasurer and CFO | Grant | A | 0.00 | 10,500 | 0 | 95,118 | 84.6 K to 95.1 K (+12.41 %) |
Feb 13 2019 | ENTA | ENANTA PHARMACEUTI ... | MELLETT PAUL J | Treasurer and CFO | Grant | A | 0.00 | 4,200 | 0 | 84,618 | 80.4 K to 84.6 K (+5.22 %) |
Feb 13 2019 | ENTA | ENANTA PHARMACEUTI ... | MELLETT PAUL J | Treasurer and CFO | Grant | A | 0.00 | 4,200 | 0 | 84,618 | 80.4 K to 84.6 K (+5.22 %) |
Jan 24 2019 | ENTA | ENANTA PHARMACEUTI ... | Gardiner Nathaniel S. | Sr. VP & General Co ... | Option Exercise | M | 34.70 | 2,000 | 69,400 | 72,700 | |
Jan 24 2019 | ENTA | ENANTA PHARMACEUTI ... | Gardiner Nathaniel S. | Sr. VP & General Co ... | Buy | M | 34.70 | 2,000 | 69,400 | 17,827 | 15.8 K to 17.8 K (+12.64 %) |
Dec 06 2018 | ENTA | ENANTA PHARMACEUTI ... | Gardiner Nathaniel S. | Sr. VP & General Co ... | Option Exercise | M | 34.70 | 2,000 | 69,400 | 74,700 | |
Dec 06 2018 | ENTA | ENANTA PHARMACEUTI ... | Gardiner Nathaniel S. | Sr. VP & General Co ... | Buy | M | 34.70 | 2,000 | 69,400 | 15,827 | 13.8 K to 15.8 K (+14.46 %) |
Dec 04 2018 | ENTA | ENANTA PHARMACEUTI ... | Ocain Tim | Senior Vice Preside ... | Option Exercise | M | 32.27 | 2,000 | 64,540 | 58,000 | |
Dec 04 2018 | ENTA | ENANTA PHARMACEUTI ... | Ocain Tim | Senior Vice Preside ... | Buy | M | 32.27 | 2,000 | 64,540 | 8,127 | 6.1 K to 8.1 K (+32.64 %) |
Nov 20 2018 | ENTA | ENANTA PHARMACEUTI ... | Gardiner Nathaniel S. | Sr. VP & General Co ... | Option Exercise | A | 81.20 | 18,000 | 1,461,600 | 18,000 | |
Nov 20 2018 | ENTA | ENANTA PHARMACEUTI ... | Ocain Tim | Senior Vice Preside ... | Option Exercise | A | 81.20 | 18,000 | 1,461,600 | 18,000 | |
Nov 20 2018 | ENTA | ENANTA PHARMACEUTI ... | MELLETT PAUL J | Treasurer and CFO | Option Exercise | A | 81.20 | 19,000 | 1,542,800 | 19,000 | |
Nov 20 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Option Exercise | A | 81.20 | 20,000 | 1,624,000 | 20,000 | |
Nov 20 2018 | ENTA | ENANTA PHARMACEUTI ... | Or Yat Sun | Sr. VP & CSO | Option Exercise | A | 81.20 | 20,000 | 1,624,000 | 20,000 | |
Nov 20 2018 | ENTA | ENANTA PHARMACEUTI ... | Luly Jay R. | President and CEO | Option Exercise | A | 81.20 | 68,000 | 5,521,600 | 68,000 | |
Oct 02 2018 | ENTA | ENANTA PHARMACEUTI ... | Gardiner Nathaniel S. | Sr. VP & General Co ... | Option Exercise | M | 34.70 | 1,500 | 52,050 | 76,700 | |
Oct 02 2018 | ENTA | ENANTA PHARMACEUTI ... | Gardiner Nathaniel S. | Sr. VP & General Co ... | Buy | M | 34.70 | 1,500 | 52,050 | 13,827 | 12.3 K to 13.8 K (+12.17 %) |
Sep 21 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Option Exercise | M | 43.46 | 2,955 | 128,424 | 72,270 | |
Sep 21 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Sell | S | 96.89 | 1,371 | 132,842 | 0 | 1.4 K to 0 (-100.00 %) |
Sep 21 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Sell | S | 95.84 | 602 | 57,699 | 1,371 | 2 K to 1.4 K (-30.51 %) |
Sep 21 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Sell | S | 94.75 | 1,229 | 116,451 | 1,973 | 3.2 K to 2 K (-38.38 %) |
Sep 21 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Sell | S | 93.90 | 453 | 42,535 | 3,202 | 3.7 K to 3.2 K (-12.39 %) |
Sep 21 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Sell | S | 93.02 | 500 | 46,509 | 3,655 | 4.2 K to 3.7 K (-12.03 %) |
Sep 21 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Buy | M | 43.46 | 2,955 | 128,424 | 4,155 | 1.2 K to 4.2 K (+246.25 %) |
Aug 21 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Option Exercise | M | 43.46 | 2,955 | 128,424 | 75,225 | |
Aug 21 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Sell | S | 93.49 | 659 | 61,613 | 310 | 969 to 310 (-68.01 %) |
Aug 21 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Sell | S | 92.68 | 2,224 | 206,130 | 969 | 3.2 K to 969 (-69.65 %) |
Aug 21 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Sell | S | 91.49 | 700 | 64,042 | 3,193 | 3.9 K to 3.2 K (-17.98 %) |
Aug 21 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Sell | S | 90.58 | 572 | 51,812 | 3,893 | 4.5 K to 3.9 K (-12.81 %) |
Aug 21 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Buy | M | 43.46 | 2,955 | 128,424 | 4,465 | 1.5 K to 4.5 K (+195.70 %) |
Jul 30 2018 | ENTA | ENANTA PHARMACEUTI ... | Luly Jay R. | President and CEO | Option Exercise | M | 11.77 | 8,498 | 99,990 | 0 | |
Jul 30 2018 | ENTA | ENANTA PHARMACEUTI ... | Luly Jay R. | President and CEO | Buy | M | 11.77 | 8,498 | 99,990 | 601,524 | 593 K to 601.5 K (+1.43 %) |
Jul 19 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Option Exercise | M | 43.46 | 2,955 | 128,424 | 78,180 | |
Jul 19 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Sell | S | 126.40 | 904 | 114,261 | 1,510 | 2.4 K to 1.5 K (-37.45 %) |
Jul 19 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Sell | S | 125.60 | 1,621 | 203,602 | 2,414 | 4 K to 2.4 K (-40.17 %) |
Jul 19 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Sell | S | 124.20 | 445 | 55,269 | 4,035 | 4.5 K to 4 K (-9.93 %) |
Jul 19 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Sell | S | 123.72 | 2,075 | 256,710 | 4,480 | 6.6 K to 4.5 K (-31.66 %) |
Jul 19 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Buy | M | 43.46 | 2,955 | 128,424 | 6,555 | 3.6 K to 6.6 K (+82.08 %) |
Jul 09 2018 | ENTA | ENANTA PHARMACEUTI ... | Luly Jay R. | President and CEO | Sell | S | 127.12 | 4,125 | 524,379 | 593,026 | 597.2 K to 593 K (-0.69 %) |
Jul 09 2018 | ENTA | ENANTA PHARMACEUTI ... | Luly Jay R. | President and CEO | Sell | S | 126.36 | 7,738 | 977,788 | 597,151 | 604.9 K to 597.2 K (-1.28 %) |
Jul 09 2018 | ENTA | ENANTA PHARMACEUTI ... | Luly Jay R. | President and CEO | Sell | S | 125.27 | 7,538 | 944,265 | 604,889 | 612.4 K to 604.9 K (-1.23 %) |
Jul 09 2018 | ENTA | ENANTA PHARMACEUTI ... | Luly Jay R. | President and CEO | Sell | S | 124.26 | 12,622 | 1,568,460 | 612,427 | 625 K to 612.4 K (-2.02 %) |
Jul 09 2018 | ENTA | ENANTA PHARMACEUTI ... | Luly Jay R. | President and CEO | Sell | S | 123.81 | 2,977 | 368,568 | 625,049 | 628 K to 625 K (-0.47 %) |
Jun 20 2018 | ENTA | ENANTA PHARMACEUTI ... | MELLETT PAUL J | Treasurer and CFO | Option Exercise | M | 1.98 | 6,960 | 13,799 | 0 | |
Jun 20 2018 | ENTA | ENANTA PHARMACEUTI ... | MELLETT PAUL J | Treasurer and CFO | Buy | M | 1.98 | 6,960 | 13,799 | 80,418 | 73.5 K to 80.4 K (+9.47 %) |
Jun 19 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Option Exercise | M | 43.46 | 2,955 | 128,424 | 81,135 | |
Jun 19 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Sell | S | 115.89 | 658 | 76,254 | 3,600 | 4.3 K to 3.6 K (-15.45 %) |
Jun 19 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Sell | S | 115.09 | 2,229 | 256,542 | 4,258 | 6.5 K to 4.3 K (-34.36 %) |
Jun 19 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Sell | S | 113.90 | 1,268 | 144,426 | 6,487 | 7.8 K to 6.5 K (-16.35 %) |
Jun 19 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Buy | M | 43.46 | 2,955 | 128,424 | 7,755 | 4.8 K to 7.8 K (+61.56 %) |
Jun 12 2018 | ENTA | ENANTA PHARMACEUTI ... | MELLETT PAUL J | Treasurer and CFO | Sell | S | 122.17 | 611 | 74,648 | 73,458 | 74.1 K to 73.5 K (-0.82 %) |
Jun 12 2018 | ENTA | ENANTA PHARMACEUTI ... | MELLETT PAUL J | Treasurer and CFO | Sell | S | 121.42 | 5,153 | 625,658 | 74,069 | 79.2 K to 74.1 K (-6.50 %) |
Jun 12 2018 | ENTA | ENANTA PHARMACEUTI ... | MELLETT PAUL J | Treasurer and CFO | Sell | S | 120.37 | 6,336 | 762,655 | 79,222 | 85.6 K to 79.2 K (-7.41 %) |
Jun 12 2018 | ENTA | ENANTA PHARMACEUTI ... | MELLETT PAUL J | Treasurer and CFO | Sell | S | 119.35 | 2,600 | 310,305 | 85,558 | 88.2 K to 85.6 K (-2.95 %) |
Jun 12 2018 | ENTA | ENANTA PHARMACEUTI ... | MELLETT PAUL J | Treasurer and CFO | Sell | S | 117.52 | 300 | 35,257 | 88,158 | 88.5 K to 88.2 K (-0.34 %) |
May 18 2018 | ENTA | ENANTA PHARMACEUTI ... | Luly Jay R. | President and CEO | Sell | S | 105.83 | 10,968 | 1,160,742 | 628,026 | 639 K to 628 K (-1.72 %) |
May 18 2018 | ENTA | ENANTA PHARMACEUTI ... | Luly Jay R. | President and CEO | Sell | S | 105.82 | 14,032 | 1,484,913 | 638,994 | 653 K to 639 K (-2.15 %) |
May 18 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Option Exercise | M | 43.46 | 2,955 | 128,424 | 84,090 | |
May 18 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Sell | S | 105.57 | 2,955 | 311,951 | 4,800 | 7.8 K to 4.8 K (-38.10 %) |
May 18 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Sell | S | 104.81 | 800 | 83,844 | 7,755 | 8.6 K to 7.8 K (-9.35 %) |
May 18 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Sell | S | 103.85 | 400 | 41,538 | 8,555 | 9 K to 8.6 K (-4.47 %) |
May 18 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Buy | M | 43.46 | 2,955 | 128,424 | 8,955 | 6 K to 9 K (+49.25 %) |
Apr 18 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Option Exercise | M | 43.46 | 2,955 | 128,424 | 87,045 | |
Apr 18 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Sell | S | 85.92 | 2,425 | 208,354 | 6,000 | 8.4 K to 6 K (-28.78 %) |
Apr 18 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Sell | S | 85.11 | 1,800 | 153,205 | 8,425 | 10.2 K to 8.4 K (-17.60 %) |
Apr 18 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Buy | M | 43.46 | 2,955 | 128,424 | 10,225 | 7.3 K to 10.2 K (+40.65 %) |
Mar 20 2018 | ENTA | ENANTA PHARMACEUTI ... | MELLETT PAUL J | Treasurer and CFO | Sell | S | 87.94 | 200 | 17,587 | 88,458 | 88.7 K to 88.5 K (-0.23 %) |
Mar 20 2018 | ENTA | ENANTA PHARMACEUTI ... | MELLETT PAUL J | Treasurer and CFO | Sell | S | 87.25 | 3,900 | 340,286 | 88,658 | 92.6 K to 88.7 K (-4.21 %) |
Mar 20 2018 | ENTA | ENANTA PHARMACEUTI ... | MELLETT PAUL J | Treasurer and CFO | Sell | S | 86.00 | 3,900 | 335,412 | 92,558 | 96.5 K to 92.6 K (-4.04 %) |
Mar 20 2018 | ENTA | ENANTA PHARMACEUTI ... | MELLETT PAUL J | Treasurer and CFO | Sell | S | 85.05 | 1,000 | 85,046 | 96,458 | 97.5 K to 96.5 K (-1.03 %) |
Mar 05 2018 | ENTA | ENANTA PHARMACEUTI ... | Vance Terry | Director | Option Exercise | A | 78.62 | 7,500 | 589,650 | 7,500 | |
Mar 05 2018 | ENTA | ENANTA PHARMACEUTI ... | Russell Lesley | Director | Option Exercise | A | 78.62 | 7,500 | 589,650 | 7,500 | |
Mar 05 2018 | ENTA | ENANTA PHARMACEUTI ... | Peterson Kristine | Director | Option Exercise | A | 78.62 | 3,750 | 294,825 | 3,750 | |
Mar 05 2018 | ENTA | ENANTA PHARMACEUTI ... | Golumbeski George | Director | Option Exercise | A | 78.62 | 7,500 | 589,650 | 7,500 | |
Mar 05 2018 | ENTA | ENANTA PHARMACEUTI ... | CARTER BRUCE L A | Director | Option Exercise | A | 78.62 | 7,500 | 589,650 | 7,500 | |
Mar 05 2018 | ENTA | ENANTA PHARMACEUTI ... | Buckley Stephen Jr. | Director | Option Exercise | A | 78.62 | 7,500 | 589,650 | 7,500 | |
Feb 13 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Payment of Exercise | F | 76.85 | 2,566 | 197,184 | 7,270 | 9.8 K to 7.3 K (-26.09 %) |
Feb 13 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Grant | A | 0.00 | 6,028 | 0 | 9,836 | 3.8 K to 9.8 K (+158.30 %) |
Feb 13 2018 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Grant | A | 0.00 | 2,500 | 0 | 3,808 | 1.3 K to 3.8 K (+191.13 %) |
Feb 13 2018 | ENTA | ENANTA PHARMACEUTI ... | Gardiner Nathaniel S. | Sr. VP & General Co ... | Payment of Exercise | F | 76.85 | 2,065 | 158,685 | 12,327 | 14.4 K to 12.3 K (-14.35 %) |
Feb 13 2018 | ENTA | ENANTA PHARMACEUTI ... | Gardiner Nathaniel S. | Sr. VP & General Co ... | Grant | A | 0.00 | 4,822 | 0 | 14,392 | 9.6 K to 14.4 K (+50.39 %) |
Feb 13 2018 | ENTA | ENANTA PHARMACEUTI ... | Gardiner Nathaniel S. | Sr. VP & General Co ... | Grant | A | 0.00 | 2,000 | 0 | 9,570 | 7.6 K to 9.6 K (+26.42 %) |
Feb 13 2018 | ENTA | ENANTA PHARMACEUTI ... | Luly Jay R. | President and CEO | Payment of Exercise | F | 76.85 | 11,132 | 855,439 | 653,026 | 664.2 K to 653 K (-1.68 %) |
Feb 13 2018 | ENTA | ENANTA PHARMACEUTI ... | Luly Jay R. | President and CEO | Grant | A | 0.00 | 20,737 | 0 | 664,158 | 643.4 K to 664.2 K (+3.22 %) |
Feb 13 2018 | ENTA | ENANTA PHARMACEUTI ... | Luly Jay R. | President and CEO | Grant | A | 0.00 | 8,600 | 0 | 643,421 | 634.8 K to 643.4 K (+1.35 %) |
Feb 13 2018 | ENTA | ENANTA PHARMACEUTI ... | MELLETT PAUL J | Treasurer and CFO | Payment of Exercise | F | 76.85 | 2,367 | 181,892 | 97,458 | 99.8 K to 97.5 K (-2.37 %) |
Feb 13 2018 | ENTA | ENANTA PHARMACEUTI ... | MELLETT PAUL J | Treasurer and CFO | Grant | A | 0.00 | 5,546 | 0 | 99,825 | 94.3 K to 99.8 K (+5.88 %) |
Feb 13 2018 | ENTA | ENANTA PHARMACEUTI ... | MELLETT PAUL J | Treasurer and CFO | Grant | A | 0.00 | 2,300 | 0 | 94,279 | 92 K to 94.3 K (+2.50 %) |
Feb 13 2018 | ENTA | ENANTA PHARMACEUTI ... | Ocain Tim | Senior Vice Preside ... | Payment of Exercise | F | 76.85 | 2,065 | 158,685 | 6,127 | 8.2 K to 6.1 K (-25.21 %) |
Feb 13 2018 | ENTA | ENANTA PHARMACEUTI ... | Ocain Tim | Senior Vice Preside ... | Grant | A | 0.00 | 4,822 | 0 | 8,192 | 3.4 K to 8.2 K (+143.09 %) |
Feb 13 2018 | ENTA | ENANTA PHARMACEUTI ... | Ocain Tim | Senior Vice Preside ... | Grant | A | 0.00 | 2,000 | 0 | 3,370 | 1.4 K to 3.4 K (+145.99 %) |
Feb 13 2018 | ENTA | ENANTA PHARMACEUTI ... | Or Yat Sun | Sr. VP & CSO | Payment of Exercise | F | 76.85 | 2,666 | 204,869 | 309,920 | 312.6 K to 309.9 K (-0.85 %) |
Feb 13 2018 | ENTA | ENANTA PHARMACEUTI ... | Or Yat Sun | Sr. VP & CSO | Grant | A | 0.00 | 6,269 | 0 | 312,586 | 306.3 K to 312.6 K (+2.05 %) |
Feb 13 2018 | ENTA | ENANTA PHARMACEUTI ... | Or Yat Sun | Sr. VP & CSO | Grant | A | 0.00 | 2,600 | 0 | 306,317 | 303.7 K to 306.3 K (+0.86 %) |
Feb 12 2018 | ENTA | ENANTA PHARMACEUTI ... | Gardiner Nathaniel S. | Sr. VP & General Co ... | Option Exercise | M | 34.70 | 4,300 | 149,210 | 78,200 | |
Feb 12 2018 | ENTA | ENANTA PHARMACEUTI ... | Gardiner Nathaniel S. | Sr. VP & General Co ... | Buy | M | 34.70 | 4,300 | 149,210 | 7,570 | 3.3 K to 7.6 K (+131.50 %) |
Nov 21 2017 | ENTA | ENANTA PHARMACEUTI ... | Gardiner Nathaniel S. | Sr. VP & General Co ... | Option Exercise | A | 48.52 | 21,500 | 1,043,180 | 21,500 | |
Nov 21 2017 | ENTA | ENANTA PHARMACEUTI ... | Ocain Tim | Senior Vice Preside ... | Option Exercise | A | 48.52 | 21,500 | 1,043,180 | 21,500 | |
Nov 21 2017 | ENTA | ENANTA PHARMACEUTI ... | MELLETT PAUL J | Treasurer and CFO | Option Exercise | A | 48.52 | 22,500 | 1,091,700 | 22,500 | |
Nov 21 2017 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Option Exercise | A | 48.52 | 23,500 | 1,140,220 | 23,500 | |
Nov 21 2017 | ENTA | ENANTA PHARMACEUTI ... | Or Yat Sun | Sr. VP & CSO | Option Exercise | A | 48.52 | 23,500 | 1,140,220 | 23,500 | |
Nov 21 2017 | ENTA | ENANTA PHARMACEUTI ... | Luly Jay R. | President and CEO | Option Exercise | A | 48.52 | 100,000 | 4,852,000 | 100,000 | |
Sep 13 2017 | ENTA | ENANTA PHARMACEUTI ... | Peterson Kristine | Director | Option Exercise | A | 42.61 | 12,500 | 532,625 | 12,500 | |
Apr 14 2017 | ENTA | ENANTA PHARMACEUTI ... | Or Yat Sun | Chief Scientific Of ... | Option Exercise | A | 14.00 | 6,963 | 97,482 | 6,963 | |
Apr 14 2017 | ENTA | ENANTA PHARMACEUTI ... | MELLETT PAUL J | Treasurer and CFO | Option Exercise | A | 14.00 | 6,963 | 97,482 | 6,963 | |
Apr 14 2017 | ENTA | ENANTA PHARMACEUTI ... | Luly Jay R. | President and CEO | Option Exercise | A | 14.00 | 13,925 | 194,950 | 13,925 | |
Apr 12 2017 | ENTA | ENANTA PHARMACEUTI ... | MELLETT PAUL J | Treasurer and CFO | Option Exercise | M | 2.97 | 29,274 | 87,058 | 0 | |
Apr 12 2017 | ENTA | ENANTA PHARMACEUTI ... | MELLETT PAUL J | Treasurer and CFO | Buy | M | 2.97 | 29,274 | 87,058 | 91,979 | 62.7 K to 92 K (+46.69 %) |
Feb 21 2017 | ENTA | ENANTA PHARMACEUTI ... | Russell Lesley | Director | Option Exercise | A | 29.02 | 2,500 | 72,550 | 2,500 | |
Feb 21 2017 | ENTA | ENANTA PHARMACEUTI ... | Vance Terry | Director | Option Exercise | A | 29.02 | 7,500 | 217,650 | 7,500 | |
Feb 21 2017 | ENTA | ENANTA PHARMACEUTI ... | Golumbeski George | Director | Option Exercise | A | 29.02 | 7,500 | 217,650 | 7,500 | |
Feb 21 2017 | ENTA | ENANTA PHARMACEUTI ... | CARTER BRUCE L A | Director | Option Exercise | A | 29.02 | 7,500 | 217,650 | 7,500 | |
Feb 21 2017 | ENTA | ENANTA PHARMACEUTI ... | Buckley Stephen Jr. | Director | Option Exercise | A | 29.02 | 7,500 | 217,650 | 7,500 | |
Feb 15 2017 | ENTA | ENANTA PHARMACEUTI ... | Or Yat Sun | Chief Scientific Of ... | Payment of Exercise | F | 29.82 | 1,079 | 32,170 | 303,717 | 304.8 K to 303.7 K (-0.35 %) |
Feb 15 2017 | ENTA | ENANTA PHARMACEUTI ... | Or Yat Sun | Chief Scientific Of ... | Grant | A | 0.00 | 2,920 | 0 | 304,796 | 301.9 K to 304.8 K (+0.97 %) |
Feb 15 2017 | ENTA | ENANTA PHARMACEUTI ... | Ocain Tim | Senior Vice Preside ... | Payment of Exercise | F | 29.82 | 830 | 24,746 | 1,370 | 2.2 K to 1.4 K (-37.73 %) |
Feb 15 2017 | ENTA | ENANTA PHARMACEUTI ... | Ocain Tim | Senior Vice Preside ... | Grant | A | 0.00 | 2,200 | 0 | 2,200 | 0 to 2.2 K |
Feb 15 2017 | ENTA | ENANTA PHARMACEUTI ... | MELLETT PAUL J | Treasurer and CFO | Payment of Exercise | F | 29.82 | 981 | 29,249 | 62,705 | 63.7 K to 62.7 K (-1.54 %) |
Feb 15 2017 | ENTA | ENANTA PHARMACEUTI ... | MELLETT PAUL J | Treasurer and CFO | Grant | A | 0.00 | 2,600 | 0 | 63,686 | 61.1 K to 63.7 K (+4.26 %) |
Feb 15 2017 | ENTA | ENANTA PHARMACEUTI ... | Luly Jay R. | President and CEO | Payment of Exercise | F | 29.82 | 2,278 | 67,919 | 634,821 | 637.1 K to 634.8 K (-0.36 %) |
Feb 15 2017 | ENTA | ENANTA PHARMACEUTI ... | Luly Jay R. | President and CEO | Grant | A | 0.00 | 6,800 | 0 | 637,099 | 630.3 K to 637.1 K (+1.08 %) |
Feb 15 2017 | ENTA | ENANTA PHARMACEUTI ... | Gardiner Nathaniel S. | Sr. VP & General Co ... | Payment of Exercise | F | 29.82 | 830 | 24,746 | 3,270 | 4.1 K to 3.3 K (-20.24 %) |
Feb 15 2017 | ENTA | ENANTA PHARMACEUTI ... | Gardiner Nathaniel S. | Sr. VP & General Co ... | Grant | A | 0.00 | 2,200 | 0 | 4,100 | 1.9 K to 4.1 K (+115.79 %) |
Feb 15 2017 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Payment of Exercise | F | 29.82 | 792 | 23,613 | 1,308 | 2.1 K to 1.3 K (-37.71 %) |
Feb 15 2017 | ENTA | ENANTA PHARMACEUTI ... | Adda Nathalie | Sr. VP & Chief Medi ... | Grant | A | 0.00 | 2,100 | 0 | 2,100 | 0 to 2.1 K |